Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Participant type

Pediatric, Patients

Age range

0-17 years, 18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Phenomena and Processes [G] - Immune system processes [G12]

Trial duration

27 Oct 2021 → 9 Mar 2026

Decision date (initial)

2024-07-19

Transition trial

Yes

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

Yes

External identifiers

EU CT number

2024-511231-94-00

EudraCT number

2020-004734-37

WHO UTN

U1111-1304-2704

ClinicalTrials.gov

NCT04640142

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Others, Pharmacokinetic, Efficacy

Primary Objective:
The primary efficacy objective of this study is to assess the efficacy of Newnorm in preventing serious bacterial infections (SBIs).
The primary pharmacokinetic (PK) objective is to confirm that weekly subcutaneous (SC) dosing of Newnorm—adjusted by a dose conversion factor (DCF) of 1.37 for patients previously treated with an intravenous immunoglobulin (IVIG) product—results in average total immunoglobulin G (IgG) levels that are statistically non-inferior to 3- or 4-weekly IVIG dosing.

Secondary objectives 4

1. 1/Assess the efficacy of Newnorm in infection control by comparing the rates of any type of infection, the time to resolution, the use of antibiotics, hospitalisations, episodes of fever, and days lost form work, school, kindergarten, or day care with historical data.
2. 2/Assess the effect of Newnorm on quality of life (QoL).
3. 3/Evaluate the tolerability and safety of Newnorm
4. The secondary PK objectives of this study are to: 1/Describe the PK characteristics of Newnorm. 2/Compare the minimum (trough) and maximum (peak) systemic levels on weekly dosing of Newnorm with 3- or 4-weekly IVIG dosing

Conditions and MedDRA coding

Human Normal Immunoglobulin

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 6

1. 1. Age of ≥2 years and ≤75 years
2. 2. Documented and confirmed diagnosis of PID as defined by European Society of Immunodeficiencies (ESID) and the Pan American Group for Immune Deficiency (PAGID) and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PID must be recorded.
3. 3. At least 12 weeks of regular treatment before the screening visit (i.e., with a stable dosing interval) with any IVIG, SCIG, or fSCIG, with a stable IgG dose between 200 and 800 mg/kg/month. A stable dose is defined as one that deviates less than ±25% from the mean dose for all infusions within this 12-week period before screening.
4. 4. Trough level of IgG ≥5 g/L at screening and documentation of an IgG trough level of ≥5 g/L at least once within the previous 12 weeks.
5. 5. Freely given written informed consent from adult patients or freely given written informed consent from the patient’s parent(s)/legal guardian(s) and written informed assent from paediatric or adolescent patients in accordance with the applicable regulatory requirements, before any study-specific procedure takes place.
6. 6. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.

Exclusion criteria 24

1. 1. Any acute infection requiring IV antibiotic treatment within 2 weeks before the screening visit or during the screening period, or any SBI within the 3 months prior to the screening visit or during the screening period.
2. 2. The patient has isolated specific antibody deficiency disorder, isolated IgG subclass deficiency, or transient hypogammaglobulinaemia of infancy.
3. 3. Current medical condition or history of condition known to cause secondary immune deficiency, for example, chronic lymphocytic leukaemia, lymphoma, multiple myeloma, or chronic or recurrent neutropenia (absolute neutrophil count <1000/µL).
4. 4. Known history of ADRs to IgA contained in other products.
5. 5. Body mass index >40 kg/m2.
6. 6. Exposure to blood or any blood product or plasma derivative other than IgG for PID within 3 months before the first infusion of Newnorm.
7. 7. History of or ongoing severe hypersensitivity, e.g., anaphylaxis or severe systemic response, or persistent reactions to blood or plasma-derived products, or to any component of Newnorm (such as glycine).
8. 8. Severe liver dysfunction (alanine aminotransferase [ALT] >3 times the upper limit of normal for the expected normal range for the testing laboratory) at screening.
9. 9. Known protein-losing enteropathies or proteinuria (known urinary protein loss of >1 g/24 h, or dipstick proteinuria of ≥3+).
10. 10. Moderate to severe renal dysfunction (per investigator discretion based on estimated glomerular filtration rate [eGFR] ≤44 mL/min/1.73 m2, as defined by KDIGO Clinical Practice Guideline) or predisposition to acute renal failure (e.g., any degree of pre-existing renal dysfunction in presence of additional acute renal failure risk factors, e.g. routine treatment with known nephrotoxic drugs).
11. 11. Uncontrolled diabetes mellitus (HbA1c > 7% / >53 mmol/mol).
12. 12. Uncontrolled arterial hypertension (systolic blood pressure of ≥ 130 mmHg for the subject under 13 years of age, ≥ 140 mmHg for subject 13 to 17 years of age, and > 160 mmHg for adults).
13. 13. Dysrhythmia/Tachycardia (resting heart rate > 100 bpm for adults/adolescents and > 120 bpm for children) and symptomatic bradycardia (resting heart rate < 60 bpm for adults, < 50 bpm for adolescents, and < 75 bpm for children in presence of symptoms e.g., low blood pressure, abnormal rhythm, chest discomfort, shortness of breath). Physiological sinus bradycardia in physically active adults/children/athletes is NOT an exclusion criterion).
14. 14. The subject has a history of or current diagnosis of deep venous thrombosis or thromboembolism (e.g. myocardial infarction, cerebrovascular accident, or transient ischemic attack); history refers to an incident in the year prior to screening or 2 episodes over lifetime.
15. 15. The subject is currently receiving anti-coagulation therapy which would make SC administration inadvisable (vitamin K antagonist, nonvitamin K antagonist oral anticoagulants [e.g. dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa], parenteral anticoagulants [e.g. fondaparinux]).
16. 16. Treatment with oral or parenteral steroids either a.at daily doses >0.3 mg/kg of prednisone (or equivalent) within the last 12 weeks before screening or b. bolus treatment of a daily dose greater than 1 mg/kg of prednisone (or equivalent) for longer than 10 days within the last 12 weeks before screening. Courses of corticosteroids (intermittent) of not more than 10 days would not exclude a patient. Inhaled or topical corticosteroids are allowed.
17. 17. Treatment with systemic immunosuppressants including chemotherapeutic agents 1 year before screening or immunomodulatory drugs 12 weeks before the screening visit.
18. 18. Live viral vaccination (such as measles, rubella, mumps, or varicella) within 1 month before the first infusion of Newnorm, during the study period, and within 3 months after last infusion of Newnorm. Note: Seasonal inactivated (killed) influenza vaccines (incl. H1N1) are allowed. COVID vaccines (mRNA vaccine and a non-replicating viral vector vaccine) are allowed.
19. 19. Treatment with any investigational medicinal product (IMP) within 3 months before the screening visit.
20. 20. Presence of any condition likely to interfere with the evaluation of Newnorm or with the compliant conduct of the study.
21. 21. Known or suspected abuse of alcohol, drugs, and/or psychotropic agents within 12 months before screening.
22. 22. Known human immunodeficiency virus (HIV)-1/2, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or positive for HIV-1/2, HBV, or HCV at screening.
23. 23. Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (refer to protocol Section 7.4.10.b) while on study and for 30 days following the last dose of study drug.
24. 24. Men who are unwilling to use birth control to prevent pregnancy for the duration of the study (unless the female partner is using a hormonal contraception, IUD or IUS, or is postmenopausal).

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. The primary endpoint of this study is the rate of SBIs (defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment. The primary efficacy endpoint will be analysed for the 52-week efficacy period. The primary PK endpoint is the average total IgG concentration (Cav) on steadystate dosing.

Secondary endpoints 7

1. Infections of any type or seriousness (including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, acute bronchitis, infectious diarrhoea, etc) (total and by category, annual rate)
2. Time to resolution of infections
3. Use of antibiotics (number of days on antibiotics and annual rate of treatment episodes) characterised as therapeutic or prophylactic use
4. Hospitalisations due to infection (number of days and annual rate)
5. Episodes of fever
6. Days lost from work, school, kindergarten, or day care due to infection
7. QoL assessments using the Child Health Questionnaire-Parent Form (CHQPF50) for patients <14 years and the SF-36 Health Survey for patients ≥14 years of age

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Sponsor organisation

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Address

Oberlaaer Strasse 235, Favoriten Favoriten

City

Vienna

Postcode

1100

Country

Austria

Scientific contact point

Organisation

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Contact name

Clinical Project Manager

Public contact point

Organisation

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Contact name

Clinical Project Manager

Third parties 7

Locations

5 EU/EEA countries · 11 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 30 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

6 submissions — initial application plus substantial / non-substantial modifications